These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33428491)

  • 1. Acetylcholinesterase inhibitors for the treatment of Alzheimer's disease - a patent review (2016-present).
    Bortolami M; Rocco D; Messore A; Di Santo R; Costi R; Madia VN; Scipione L; Pandolfi F
    Expert Opin Ther Pat; 2021 May; 31(5):399-420. PubMed ID: 33428491
    [No Abstract]   [Full Text] [Related]  

  • 2. Old and new acetylcholinesterase inhibitors for Alzheimer's disease.
    Galimberti D; Scarpini E
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1181-7. PubMed ID: 27459153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent Acetylcholinesterase Inhibitors: Potential Drugs for Alzheimer's Disease.
    Akıncıoğlu H; Gülçin İ
    Mini Rev Med Chem; 2020; 20(8):703-715. PubMed ID: 31902355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Butyrylcholinesterase inhibitors as potential anti-Alzheimer's agents: an updated patent review (2018-present).
    Fernández-Bolaños JG; López Ó
    Expert Opin Ther Pat; 2022 Aug; 32(8):913-932. PubMed ID: 35623095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Memantine Derivatives as Multitarget Agents in Alzheimer's Disease.
    Marotta G; Basagni F; Rosini M; Minarini A
    Molecules; 2020 Sep; 25(17):. PubMed ID: 32887400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).
    McHardy SF; Wang HL; McCowen SV; Valdez MC
    Expert Opin Ther Pat; 2017 Apr; 27(4):455-476. PubMed ID: 27967267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by Indication.
    Huisa BN; Thomas RG; Jin S; Oltersdorf T; Taylor C; Feldman HH
    J Alzheimers Dis; 2019; 67(2):707-713. PubMed ID: 30636733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donepezil: an important prototype to the design of new drug candidates for Alzheimer's disease.
    Rodrigues Simões MC; Dias Viegas FP; Moreira MS; de Freitas Silva M; Riquiel MM; da Rosa PM; Castelli MR; dos Santos MH; Soares MG; Viegas C
    Mini Rev Med Chem; 2014 Jan; 14(1):2-19. PubMed ID: 24251806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioural effects of novel multitarget anticholinesterasic derivatives in Alzheimer's disease.
    Giménez-Llort L; Ratia M; Pérez B; Camps P; Muñoz-Torrero D; Badia A; Clos MV
    Behav Pharmacol; 2017 Apr; 28(2 and 3-Spec Issue):124-131. PubMed ID: 28125507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.
    Andrisano V; Naldi M; De Simone A; Bartolini M
    Expert Opin Ther Pat; 2018 Jun; 28(6):455-465. PubMed ID: 29757691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacrine derivatives and Alzheimer's disease.
    Tumiatti V; Minarini A; Bolognesi ML; Milelli A; Rosini M; Melchiorre C
    Curr Med Chem; 2010; 17(17):1825-38. PubMed ID: 20345341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromones: privileged scaffolds for the production of multi-target-directed-ligand agents for the treatment of Alzheimer's disease.
    Silva CFM; Pinto DCGA; Silva AMS
    Expert Opin Drug Discov; 2018 Dec; 13(12):1141-1151. PubMed ID: 30430870
    [No Abstract]   [Full Text] [Related]  

  • 13. Developments with multi-target drugs for Alzheimer's disease: an overview of the current discovery approaches.
    González JF; Alcántara AR; Doadrio AL; Sánchez-Montero JM
    Expert Opin Drug Discov; 2019 Sep; 14(9):879-891. PubMed ID: 31165654
    [No Abstract]   [Full Text] [Related]  

  • 14. A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease.
    Korabecny J; Spilovska K; Mezeiova E; Benek O; Juza R; Kaping D; Soukup O
    Curr Med Chem; 2019; 26(30):5625-5648. PubMed ID: 29768996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's disease.
    Relkin NR
    Expert Rev Neurother; 2007 Jun; 7(6):735-48. PubMed ID: 17561789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in the Prescription and Long-Term Utilization of Antidementia Drugs Among Patients with Alzheimer's Disease in Spain: A Cohort Study Using the Registry of Dementias of Girona.
    Calvó-Perxas L; Turró-Garriga O; Vilalta-Franch J; Lozano-Gallego M; de Eugenio R; Márquez F; Carmona O; Gich J; Manzano A; Viñas M; Roig AM; Garre-Olmo J;
    Drugs Aging; 2017 Apr; 34(4):303-310. PubMed ID: 28258538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer's Disease.
    Pérez DI; Martínez A; Gil C; Campillo NE
    Curr Med Chem; 2015; 22(33):3789-806. PubMed ID: 26264921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of oxidative stress and other pathologies in Alzheimer's disease.
    Simunkova M; Alwasel SH; Alhazza IM; Jomova K; Kollar V; Rusko M; Valko M
    Arch Toxicol; 2019 Sep; 93(9):2491-2513. PubMed ID: 31440798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine.
    Zemek F; Drtinova L; Nepovimova E; Sepsova V; Korabecny J; Klimes J; Kuca K
    Expert Opin Drug Saf; 2014 Jun; 13(6):759-74. PubMed ID: 24845946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A molecular approach in drug development for Alzheimer's disease.
    Agatonovic-Kustrin S; Kettle C; Morton DW
    Biomed Pharmacother; 2018 Oct; 106():553-565. PubMed ID: 29990843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.